申请人:Janssen Pharmaceutica NV
公开号:US20170313691A1
公开(公告)日:2017-11-02
The present invention comprises compounds of Formula I.
wherein:
A
1
, A
2
, A
3
, A
4
, A
5
, R
1
, and R
2
are defined in the specification.
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
本发明涵盖了Formula I的化合物。
其中:
A1,A2,A3,A4,A5,R1和R2在说明书中有定义。
该发明还涵盖了一种治疗或改善综合症、疾病或疾病的方法,其中该综合症、疾病为类风湿性关节炎或牛皮癣。该发明还涵盖了通过给哺乳动物施用Formula I中至少一种化合物的治疗有效量来调节RORγt活性的方法。